Paragard IUD Risk Information Omitted from Advertisements, FDA Warns

Federal regulators have sent a warning letter to CooperSurgical, Inc., indicating the manufacturer failed to include important information about the risks with Paragard IUD birth control implant in recent advertisements.

The FDA issued the warning letter on February 23, saying a direct-to-consumer video advertisement contained false or misleading information, which fails to communicate risk information. In addition, CooperSurgical did not submit the ad for review by the FDA in a timely matter, according to the Office of Prescription Drug Promotion (OPDP), which actually classifies the implant as a drug product.

Paragard is a T-shaped intrauterine device (IUD), which is placed in the uterus to provide women long-active protection against pregnancy for up to ten years. It is marketed as a safe and easily reversible form of birth control, where doctors are able to remove the IUD during an office procedure when a woman wants to conceive. However, the device does carry serious risks and a growing number of women are now reporting severe and debilitating injuries after the Paragard IUD broke or fractured during a removal procedure.

Learn More About

Paragard IUD Lawsuits

Women have reported problems where Paragard IUD fractured or broken during removal, resulting in serious injury.

Coopersurgical and earlier manufacturers now face a growing number of ParaGard IUD lawsuits that are being filed in courts nationwide, each raising similar allegations that the product was defectively designed and manufactured, making it prone to fail during removal, often resulting in the need for women to undergo invasive surgery to remove fragments, or a total hysterectomy that impacts their ability to have children in the future.

According to the FDA, CooperSurgical’s direct-to-consumer ad, entitled “Paragard: Family Planning During the Pandemic”, which aired on WBTS’s The Hub Today on October 5, 2020, did not communicate any risks about the ParaGard implant.

“By omitting the risks associated with Paragard, the video fails to provide material information about the consequences that may result from the use of the drug and creates a misleading impression about the drug’s safety,” the FDA letter warns. “This misleading presentation is particularly concerning from a public health perspective due to the serious and potentially life-threatening risks associated with the drug, such as those contained in the WARNINGS AND PRECAUTIONS section of Paragard’s PI (prescriber information).”

The FDA is calling on CooperSurgical to submit a comprehensive plan to “disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter.”

According to allegations raised in the growing Paragard litigation, even the current risk information provided in other advertisements does not sufficiently disclose the problems encountered during Paragard IUD removal, even when doctors follow the recommended safety precautions.

Given common questions of fact and law raised in more than 100 complaints filed throughout the federal court system in recent months, the U.S. Judicial Panel on Multidistrict Litigation (JPML) decided last month to consolidate all discovery and pretrial proceedings before U.S. District Judge Leigh Martin May in the Northern District of Georgia, as part of a federal MDL, or multidistrict litigation.

As part of the coordinated proceedings, it is expected Judge May will establish a “bellwether” process, where a small group of representative claims will be prepared for early trial dates to help gauge how juries may respond to certain evidence and testimony that will be presented throughout other cases.

While the outcome for these early trials would not be binding on other plaintiffs, they may facilitate potential ParaGard IUD settlements that would avoid the need for dozens, or possibly hundreds, of cases to be set for individual trials throughout the federal court system in the coming years.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.